| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | Bone Marrow Stromal Antigen 1, BST-1, ADP-Ribosyl Cyclase 2, Cyclic ADP-ribose hydrolase 2, CADPr Hydrolase 2, CADPR2, LY-65 |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-CD157/BST1 (extracellular) Antibody is an antibody targeting Bone Marrow Stromal Antigen 1, BST-1, ADP-Ribosyl Cyclase 2, Cyclic ADP-ribose hydrolase 2, CADPr Hydrolase 2, CADPR2, LY-65 Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in IFC, IHC, LCI, WB to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: Bone Marrow Stromal Antigen 1, BST-1, ADP-Ribosyl Cyclase 2, Cyclic ADP-ribose hydrolase 2, CADPr Hydrolase 2, CADPR2, LY-65 (also reported as Bone Marrow Stromal Antigen 1, BST-1, ADP-Ribosyl Cyclase 2, Cyclic ADP-ribose hydrolase 2, CADPr Hydrolase 2, CADPR2, LY-65).
- Immunogen/epitope region: Extracellular, N-terminus..
- Homology note: Mouse, Rat - 15 out of 16 amino acid residues identical Not recommended for BST1 from human samples (informative for cross-species interpretation).
- Species reactivity (as provided): Rat, Mouse.
- Lot quality control (as provided): Western blot analysis.
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
- Conjugate/format: Unconjugated (may affect detection channel and background).
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
CD157, also known as bone marrow stromal cell antigen 1 (BST1), is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a dual function as a receptor and a β-NAD+-metabolizing ectoenzyme of the ADP-ribosyl cyclases gene family1.CD157 and its paralog CD38, catalyze the formation of cyclic ADP-ribose (cADPR) from NAD, a second messenger involved in intracellular calcium mobilization through ryanodine receptors, among other functions 1,2.As a receptor, CD157 interacts with β1 and β2 integrins (CD29 and CD18 respectively) to form a multimolecular complex that mediates intracellular signaling through the FAK/Src pathway 1-3. Known ligands for CD157 include extracellular matrix components like fibronectin, fibrinogen, laminin-1 and type 1 collagen 2,3.As it name suggests, CD157 was first identified in bone marrow-derived cells, but it is also expressed in other immune system cells like neutrophils, T-cells, pre B-cells and macrophages. CD157 has been demonstrated to be involved in both the innate and adaptive immune response with roles in B- and T-cell growth and the control of myeloid cells migration during inflammation 1.CD157 is considered a marker and therapeutic target for several hematological malignancies like acute myeloid leukemia (AML) as well as several solid tumors like ovarian and malignant mesothelioma 3,4,5.Outside the immune system, CD157 is expressed in vascular endothelium, intestine and brain among others.
Research relevance and current trends
- Profiling immune-marker expression across cell subsets with single-cell or flow-based readouts.
- Connecting receptor/ligand levels to activation state and cytokine programs.
- Applying genetic perturbation or orthogonal assays to support specificity and interpretation.
Common research applications
- Western blot (WB): compare target abundance/size across lysates and conditions; consider isoforms/PTMs.
- Immunohistochemistry (IHC): examine spatial distribution in tissue and relate signal to cell-type composition.
- Immunofluorescence/ICC: assess subcellular localization and co-localization with markers in cells or sections.
- Flow cytometry (direct/indirect): quantify target-positive populations and shifts in expression across subsets.
- Live cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Provided control suggestions: Negative control: BLP-NT067.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-NT067; Negative control: BLP-NT067.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
